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Abstract
Background: Reducing mortality from HIV-associated tuberculosis (TB) requires diagnostic tools that are rapid and
have high sensitivity among patients with poor prognosis. We determined the relationship between disease severity
and the sensitivity of new sputum-based and urine-based diagnostic assays.
Methods: Consecutive ambulatory patients enrolling for antiretroviral treatment in South Africa were screened for
TB regardless of symptoms using diagnostic assays prospectively applied to sputum (fluorescence smear
microscopy, Xpert MTB/RIF and liquid culture (reference standard)) and retrospectively applied to stored urine
samples (Determine TB-LAM and Xpert MTB/RIF). Assay sensitivities were calculated stratified according to
pre-defined indices of disease severity: CD4 count, symptom intensity, serum C-reactive protein (CRP), hemoglobin
concentration and vital status at 90 days.
Results: Sputum culture-positive TB was diagnosed in 15% (89/602) of patients screened and data from 86 patients
were analyzed (median CD4 count, 131 cells/μL) including 6 (7%) who died. The sensitivity of sputum microscopy
was 26.7% overall and varied relatively little with disease severity. In marked contrast, the sensitivities of urine-based
and sputum-based diagnosis using Determine TB-LAM and Xpert MTB/RIF assays were substantially greater in
sub-groups with poorer prognosis. Rapid diagnosis from sputum and/or urine samples was possible in >80% of
patients in sub-groups with poor prognosis as defined by either CD4 counts <100 cells/μL, advanced symptoms,
CRP concentrations >200 mg/L or hemoglobin <8.0 g/dl. Retrospective testing of urine samples with Determine
TB-LAM correctly identified all those with TB who died.
Conclusions: The sensitivities of Xpert MTB/RIF and Determine TB-LAM for HIV-associated TB were highest among
HIV-infected patients with the most advanced disease and poorest prognostic characteristics. These data provide
strong justification for large-scale intervention studies that assess the impact on survival of screening using these
new sputum-based and urine-based diagnostic approaches.
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Background
Tuberculosis (TB) remains the leading cause of HIV-
related mortality worldwide, accounting for approximately
one quarter of HIV/AIDS deaths [1]. A majority of these
deaths occur in sub-Sahara Africa, which bears 79% of the
global burden of HIV-associated TB [1]. Very high frequen-
cies of undiagnosed disseminated TB have been reported in
post-mortem studies of people dying with HIV/AIDS in
sub-Saharan Africa both before and during the scale-up
of antiretroviral treatment (ART) [2-5]. These data suggest
that the true contribution of TB to HIV-related deaths
may be underestimated and that failure of ante-mortem
diagnosis is a major problem [6].
A number of factors undermine TB diagnosis in people
with advanced HIV-related immunodeficiency [7,8]. The
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clinical presentation is often non-specific, with only a
minority of patients with proven pulmonary disease
reporting chronic cough of more than two weeks dur-
ation [9,10]. Extrapulmonary and disseminated forms
of the disease are common and difficult to diagnose
[7,8]. In resource-limited settings, heavy reliance is still
placed on outdated TB diagnostic tests, such as sputum
smear microscopy and chest radiography, both of which
have limited diagnostic accuracy in those with advanced
immunodeficiency [7,11]. Where culture is available,
diagnosis may take several weeks. Thus, TB diagnoses
are often either delayed or missed in those with poor
immune function and high risk of death.
Over the past few years, considerable progress has
been made in the development of new, rapid assays for
TB that have useful diagnostic accuracy in patients living
with HIV [11-13]. These assays include the Xpert MTB/
RIF (Cepheid Inc., Sunnyvale, CA, USA) rapid molecular
assay, which can be applied to both respiratory and
non-respiratory samples [11]. In addition, the Determine
TB-LAM assay (Alere Inc., Waltham, MA, USA) is a sim-
ple lateral-flow (strip-test) that detects lipoarabinomannan
(LAM) in urine [13]. We have previously reported on the
useful diagnostic accuracy of these two assays during
active screening of patients prior to starting ART in a
South African township [13-15]. However, for new assays
to reduce deaths from HIV-associated TB, they must have
adequate sensitivity among patients with poor prognosis
and highest risk of death. In the present analysis, we there-
fore ascertained how the sensitivities of urine- and sputum-
based approaches to diagnosis using the Xpert MTB/RIF
and Determine TB-LAM assays varied according to disease
severity as reflected by CD4 cell count, symptom intensity,
C-reactive protein (CRP) concentration, hemoglobin con-
centration and vital status at 90 days of follow-up.
Methods
The ART services in Gugulethu Township in Cape Town
with its high burden of TB and mortality have all previously
been described in detail [16-19]. Between 12 March 2010
and 20 April 2011, consecutive patients newly referred to
start ART and who were aged >18 years, ART-naive and
had no current TB diagnosis were consecutively recruited
regardless of symptoms as previously described [13]. All
participants provided written informed consent and the
study was approved by the research ethics committees of
the University of Cape Town, South Africa, and the London
School of Hygiene & Tropical Medicine, UK.
Patients were clinically characterized, routine baseline
investigations were done and then they were screened for
TB. The standardized symptom-screening questionnaire
included the World Health Organization (WHO) symptom
screen (the presence of more than one of the following
symptoms: cough, fever, weight loss or night sweats [9]).
Two sputum samples were requested from each patient;
a spot specimen was followed by a second that was in-
duced using nebulized 3% hypertonic saline. If neces-
sary, both specimens were induced. Urine samples were
collected and stored at −20°C. Blood CD4 cell counts
and plasma viral load were measured on all patients via
the routine laboratory services. Chest radiographs were
obtained and reported by an experienced reader certified
in the use of the chest radiograph reading and recording
system [20,21].
Laboratory procedures
Sputum specimens were processed using standardized
protocols and external quality assurance procedures by
a centralized accredited laboratory as previously described
[13]. Samples were decontaminated with N-acetyl-L-
cysteine and sodium hydroxide and concentrated by
centrifugation. Smears prepared from the sputum pel-
lets were stained with auramine O fluorescent stain for
fluorescence microscopy and equal volumes of the
remaining pellet were tested by liquid culture and the
Xpert MTB/RIF assay. All smears graded as scanty, 1+,
2+ and 3+ were defined as ‘smear-positive’. Cultures
were performed using Mycobacterial Growth Indicator
Tubes (MGIT, Becton Dickinson, Sparks, MD, USA)
and were incubated for up to six weeks. Cultures positive
for acid-fast bacilli were identified as Mycobacterium
tuberculosis complex using the MTBDRplus assay (Hain
Lifesciences, Nehren, Germany). Xpert MTB/RIF assays
were done according to the manufacturer’s instructions.
The results of all tests were read by technologists blinded
to the outcomes of the other assays.
Frozen urine samples were defrosted and retrospectively
analyzed for the presence of lipoarabinomannan (LAM)
using the commercially available Determine TB-LAM
lateral-flow assay. Positive results were recorded when the
test band had equal or greater intensity to the weakest band
on the reference card. Defrosted urine samples (2.0 mL)
were also concentrated by centrifugation, resuspended in
0.75 mL of phosphate buffer and tested retrospectively
using the Xpert MTB/RIF assay.
Concentrations of CRP were measured in duplicate
serum samples using the Quantikine enzyme-linked
immunosorbent assay (R&D Systems Inc., Minneapolis,
MN, USA) according to the manufacturer’s instructions.
Patient outcomes
Patients were followed up within the routine ART ser-
vice and patients diagnosed as having TB were referred
to treatment clinics within the township. The time to
initiation of TB treatment was ascertained and ART service
patient records were reviewed to determine vital status at
three months.
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Definitions and analysis
Patients were defined as having TB if M. tuberculosis
was cultured from one or more sputum samples. TB pa-
tients were then categorized according to CD4 cell count
(>200, 101 to 200 and <200 cells/μL), symptom profile,
serum CRP concentration (using strata approximating
to quartiles), hemoglobin concentration (using strata cor-
responding to the WHO classification of anemia [22]) and
vital status after three months follow-up, providing stratifi-
cation by disease severity. Patients were characterized using
simple descriptive statistics. The sensitivity of the Xpert
MTB/RIF and Determine TB-LAM assays were then calcu-
lated for patient groups stratified by the pre-defined indices
of disease severity and using culture as the reference stand-
ard. Assay sensitivities across these strata were compared
using the chi-square and Fisher’s exact tests as appropriate.
All statistical tests were two-sided at alpha = 0.05.
Results
Patients and TB diagnoses
Of 604 consecutive patients who fulfilled eligibility criteria,
602 agreed to participate. Sputum samples could be
obtained from 542 (90.0%) patients. Smear microscopy,
culture and Xpert MTB/RIF results were available from
one or more sputum samples from 523 patients (Figure 1).
Of 89 patients diagnosed with sputum culture-positive TB,
data permitting stratification by disease severity were
available for 86. Of these, additional data on urine-based
diagnostics were available for 81 patients.
Patients with TB (n = 86) had a median age of 33.1 years
(IQR, 28.3 to 39.9) and 64% were female. The median
CD4 cell count was 131 cells/μL (IQR, 52 to 204) and
47.7% had WHO stage 3 or 4 disease prior to TB screening.
The median hemoglobin was 10.8 g/dL (IQR, 8.8 to 12.0)
and the median CRP concentration was 57.8 mg/L (IQR,
20.3 to 202.7; range, 1.7 to 560). Symptom severity was
classified into three mutually exclusive groups: those with a
negative WHO symptom screen (n = 15), those with a posi-
tive WHO symptom screen but without cough of two or
more weeks’ duration (n = 49) and those with a positive
WHO symptom screen including a cough of two or more
weeks’ duration (n = 22).
Among the culture-confirmed cases of TB (n = 86),
the time to positivity in liquid culture was prolonged
(median, 16 days; IQR, 11 to 21). Among 83 patients with
evaluable chest radiographs, any radiological abnormal-
ity was observed in 61 (73.5%), central abnormalities
(mediastinal and hilar lymphadenopathy) were observed
in 23 (27.7%), parenchymal abnormalities in 57 (66.3%)
and pleural abnormalities in 17 (20.5%). The median
number of radiographic zones involved with parenchymal
abnormalities was two out of six (IQR, 0 to 4) but was
greater in the sub-set of patients with prolonged cough
(median, four zones; IQR, 2 to 5).
Indices of disease severity
Patients with TB (n = 86) were next stratified using four
different indices of disease severity: CD4 cell count
542 patients with 1052 sputum samples
523 patients with ≥1 sputum culture, ≥1sputum  
Xpert and sputum AFB microscopy result
602 eligible patients enrolled
60 patients could not produce sputum
89  patients had TB diagnosed by ≥1 positive  
culture result
86 patients with culture-positive TB with data 
permitting analysis stratified by disease severity.
Urine diagnostics data available for 81 patients.
19 patients had no Xpert results  
(tests not done for 17)
3 patients had no CRP results
5 patients with missing urine samples
431 patients had tuberculosis excluded by
negative culture results 
Figure 1 Flow diagram showing the numbers of patients studied.
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(<100, 100 to 200 and >200 cells/μL), increasing symp-
tom severity (as defined above), CRP concentration
(<20, 20 to 60, 61 to 200 and >200 mg/L) and
hemoglobin concentration (<8, 8 to 11 and >11 g/dL).
Table 1 shows the characteristics of these groups of patients
stratified by these indices and confirms that patients in
poorer prognostic groups had other adverse characteris-
tics. In contrast, when patients were grouped according
to the presence or absence of chest radiographic ab-
normalities, it was clear that radiographic appearances
in this patient group did not provide a useful index of
disease severity (data not shown).
Sensitivity of TB diagnostics and disease severity
The diagnostic sensitivities of the various sputum-based
and urine-based assays differed substantially. The overall
sensitivities ranked in descending order were 70.9% (95%
CI, 60.1 to 80.2), 58.1% (95% CI, 47.0 to 68.7), 29.6%
(95% CI, 20.0 to 40.8), 26.7% (95% CI, 17.8 to 37.4) and
18.5% (95% CI, 10.8 to 28.7) when using Xpert MTB/RIF
(two sputum samples), Xpert MTB/RIF (one sputum
sample), sputum smear microscopy, Determine TB-LAM
(urine) and Xpert MTB/RIF (urine), respectively. However,
the sensitivities of these assays varied substantially ac-
cording to disease severity (Figure 2).
The predominant pattern that emerged from these
analyses was that the sensitivities of both urine-based
and sputum-based assays tended to be higher among
those with lower CD4 cell counts (Figure 2a), more ad-
vanced symptoms (Figure 2b), higher CRP concentra-
tions (Figure 2c) and lower hemoglobin concentrations
(Figure 2d). These data indicate that rapid diagnosis
from sputum and/or urine samples using Xpert MTB/RIF
and/or Determine TB-LAM was possible in >80% of
patients categorized in the four groups with worst
prognosis (CD4 count <100 cells/μL, advanced symptoms,
CRP ≥200 mg/L and hemoglobin <8.0 g/dl).
The association between disease severity and diagnostic
sensitivity was weakest for sputum smear microscopy for
which there was no significant association with CD4 count
(Figure 2a) or CRP concentration (Figure 2c). The sensi-
tivity of smear microscopy did not exceed 50.0% in any of
the patient sub-groups. In contrast, the sensitivity of Xpert
MTB/RIF when testing either one or two sputum samples
was substantially greater when comparing the most favor-
able and least favorable prognostic sub-groups for all of the
four indices of disease severity. The median increments in
sensitivity were 47.0% (range 27.7 to 50.6) when testing
one sputum sample and 34.4% (range, 27.4 to 47.6) when
testing two samples.
Although the overall sensitivity of Determine TB-LAM
was low, the associations between the sensitivity of
Determine TB-LAM point-of-care assay for urine lipoara-
binomannan and disease severity were extremely striking
(Figure 2). In all of the least favorable prognostic categories,
Determine TB-LAM detected a majority of cases, with sen-
sitivity ranging from 51.7% to 100%. When comparing the
most favorable and least favorable prognostic categories for
each of the four indices of disease severity, the median
increment in sensitivity was 53.3% (range, 38.1 to 100.0).
The association between the sensitivity of Xpert MTB/
RIF when testing urine samples and disease severity
was strong for each of the indices with the exception of
symptom severity (Figure 2). In the least favorable
prognostic categories, sensitivities ranged from 28.6%
to 50.0%. When comparing the most favorable and least
favorable prognostic categories for each of the four indices
of disease severity, the median increment in sensitivity
was 33.9% (range, 7.2 to 43.9).
Vital status during follow-up and sensitivity of TB diagnostics
We next assessed how the diagnostic sensitivity of the
assays differed according to vital status at 90 days of
follow-up (Figure 3). There was no significant association
between the sensitivity of sputum tests (smear microscopy
and Xpert MTB/RIF) and vital status, although the sensi-
tivity of Xpert MTB/RIF tended to be higher among those
who died. In contrast, despite limited statistical power,
there was a very strong relationship between the sensi-
tivity of urine-based tests and vital status at 90 days
(Figure 3). The sensitivities of Determine TB-LAM and
of Xpert MTB/RIF testing of urine were 75.0% and 65.5%
higher, respectively, among patients who died compared
to those who survived.
We next plotted Venn diagrams to reveal the relationship
between the sensitivities of the different diagnostic ap-
proaches for culture-positive TB cases and for the sub-
set who had died during 90 days of follow-up (Figure 4).
In contrast to sputum smear microscopy, Xpert MTB/RIF
testing of two sputum samples or testing of urine using
Determine TB-LAM was able to diagnose TB among all
those patients who subsequently died.
Discussion
Since the advent of the AIDS pandemic, the lack of rapid
and accurate assays for HIV-associated TB in those with
advanced immunodeficiency has been a major hindrance
to reducing deaths from these diseases in resource-limited
settings [6]. We found a very high prevalence of culture-
positive TB, but diagnosis with conventional tests was
challenging. Only one quarter of cases were sputum smear-
positive, 26% had normal chest radiographs and the median
time to culture positivity was 16 days. However, the key
finding of this study was that compared to smear micros-
copy, the incremental diagnostic sensitivity provided by the
Xpert MTB/RIF assay (applied to sputum or urine samples)
and the Determine TB-LAM urine test were greatest among
the patients with the worst prognostic characteristics:
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Table 1 Characteristics of patients (n = 86) with tuberculosis (TB) stratified by indices of disease severity and survival
Blood CD4 cell count Symptom severity C-reactive protein Hemoglobin concentration Vital status at
90 days(cells/μL) Concentration (mg/L) (g/dL)
>200 101 to
200
0 to 100 WHO
screen
negative
WHO screen
positive +
cough
<2 weeks
WHO screen
positive +
cough
≥2 weeks
<20 20 to 60 61 to
200
>200 >11.0 8.0 to
11.0
<8.0 Alive at
90 days
Death at
90 days
(n = 24) (n = 28) (n = 34) (n = 15) (n = 49) (n = 22) (n = 21) (n = 23) (n = 19) (n = 23) (n = 34) (n = 36) (n = 12) (n = 80) (n = 6)
Patient
characteristics
Age, median (IQR) 32.9 (28.6
to 39.0)
31.1 (28.2
to 35.8)
35.5 (25.8
to 44.5)
31.5 (28.6
to 45.9)
33.7 (28.5 to
38.0)
30.5 (26.6
to 39.3)
33.7 (30.7
to 38.0)
35.5 (28.6
to 42.5)
35.2 (28.3
to 44.5)
30.6 (25.5
to 35.6)
35.3 (30.3
to 45.9)
32.9 (26.3
to 40.5)
27.6 (25.0
to 33.1)
32.5 (28.4
to 38.7)
38.6 (26.6
to 44.5)
Female (%) 14 (58.3) 19 (67.9) 22 (64.7) 10 (66.7) 32 (65.3) 13 (59.1) 13 (61.9) 16 (69.6) 13 (68.4) 13 (56.5) 14 (41.2) 29 (80.6) 9 (75.0) 51 (63.8) 4 (66.7)
BMI, median (IQR) 21.2 (20.1
to 24.0)
21.0 (19.7
to 27.4)
21.9 (18.7
to 25.9)
22.6 (19.7
to 27.6)
21.2 (19.3
to 25.0)
21.0 (18.0
to 22.3)
22.0 (20.7
to 27.1)
22.7 (20.9
to 27.6)
20.1 (17.7
to 22.1)
20.6 (18.4
to 24.3)
21.3 (20.6
to 24.5)
21.6 (18.2
to 27.1)
19.8 (17.8
to 24.0)
21.3 (19.6
to 26.0)
18.9 (17.0
to 24.0)
History of previous
TB (%)
4 (16.7) 8 (28.6) 5 (14.7) 6 (40.0) 7 (14.3) 4 (18.2) 5 (23.8) 4 (17.4) 2 (10.5) 6 (26.1) 7 (20.6) 8 (22.2) 1 (8.3) 16 (20.0) 1 (16.7)
WHO stage at
enrolment
1 or 2 (%) 16 (66.7) 18 (64.3) 11 (32.4) 9 (60.0) 27 (55.1) 9 (40.9) 17 (81.0) 15 (65.2) 4 (21.1) 9 (39.1) 22 (64.7) 16 (44.4) 3 (25.0) 45 (56.3) 0
3 or 4 (%) 8 (33.3) 10 (35.7) 23 (67.7) 6 (40.0) 22 (44.9) 13 (59.1) 4 (19.1) 8 (34.8) 15 (79.0) 14 (60.9) 12 (35.3) 20 (55.6) 9 (75.0) 35 (43.8) 6 (100)
Blood Tests
Hemoglobin
g/dL (IQR)
11.5 (10.7
to 13.7)
10.5 (8.5
to 12.7)
9.4 (8.0
to 11.0)
11.5 (10.6
to 13.4)
10.9 (8.9
to 12.0)
8.8 (8.0
to 11.0)
11.7 (11.3
to 14.1)
11.1 (8.8
to 12.3)
10.1 (7.9
to 11.6)
9.0 (7.9
to 10.0)
12.5 (11.7
to 13.9)
9.5 (8.8
to 10.6)
7.3 (7.0
to 7.6)
10.9 (8.8
to 12.3)
9.9 (7.2
to 10.1)
Absolute neutrophil
count cells/μL (IQR)
3.3 (2.5
to 4.7)
3.2 (2.4
to 4.3)
4.0 (2.5
to 6.7)
2.6 (1.9 to
3.5)
3.3 (2.4
to 5.3)
4.7 (3.0
to 7.0)
2.5 (1.9
to 3.3)
3.2 (2.5
to 5.0)
5.0 (3.4
to 6.7)
4.3 (2.6
to 9.1)
2.8 (2.0
to 3.5)
3.6 (2 .8
to 5.1)
7.2 (4.4
to 9.4)
3.3 (2.4
to 5.2)
4.9 (4.0
to 6.2)
Absolute lymphocyte
count, cells/μL (IQR)
1.9 (1.6
to 2.2)
1.9 (1.4
to 2.7)
0.8 (0.6
to 1.3)
1.9 (1.3 to
2.7)
1.6 (1.1
to 2.0)
1.1 (0.7
to 1.7)
1.6 (1.4
to 2.7)
1.7 (1.0
to 2.2)
1.3 (0.6
to 1.7)
1.4 (0.7
to 2.1)
1.6 (1.3
to 2.3)
1.5 (0.9
to 2.0)
0.5 (0.4
to 1.2)
1.6 (1.1
to 2.1)
0.7 (0.6
to 0.7)
CD4 cell counts
(cells/μl)
Median (IQR) 233 (211
to 275)
143 (124
to 184)
35 (21
to 68)
158 (44 to
189)
137 (68
to 213)
109 (35
to 184)
188 (138
to 235)
158 (71
to 205)
52 (21
to 205)
102 (29
to 140)
189 (114
to 235)
98 (41 to
194)
28 (16
to 107)
139 (66 to
205)
34 (29
to 62)
CD4 0 to 100 - - 34 (100) 5 (33.3) 19 (38.8) 10 (45.5) 3 (14.3) 8 (34.8) 12 (63.2) 11 (47.8) 8 (23.5) 18 (50.0) 8 (66.7) 29 (36.3) 5 (83.3)
CD4 101 to 200 - 28 (100) - 7 (46.7) 13 (26.5) 8 (36.4) 8 (38.1) 8 (34.8) 1 (5.3) 11 (47.8) 11 (32.4) 9 (25.0) 4 (33.3) 27 (33.8) 1 (16.7)
CD4 >200 24(100) - - 3 (20.0) 17 (34.7) 4 (18.2) 10 (47.6) 7 (30.4) 6 (31.6) 1 (4.4) 15 (44.1) 9 (25.0) 0 24 (30.0) 0
Log viral load
(copies/ml)
Median (IQR) 4.7 (4.2
to 5.0)
4.6 (4.2
to 5.3)
5.1 (4.7
to 5.5)
4.7 (4.2 to
5.0)
4.8 (4.4
to 5.3)
4.9 (4.5
to 5.4)
4.7 (4.4
to 4.8)
4.7 (4.4
to 5.2)
4.9 (4.5
to 5.6)
5.2 (4.7
to 5.6)
4.4 (3.9
to 4.7)
5.1 (4.8
to 5.4)
5.6 (5.1
to 5.7)
4.8 (4.4
to 5.3)
5.5 (4.9
to 5.7)
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those with the CD4 cell counts <100 cells/μL, advanced
symptoms, CRP concentrations >200 mg/L or severe
anemia (<8.0 g/dL) and in those who subsequently died.
These data indicate that screening sputum and/or urine
and samples from patients using these new diagnostic ap-
proaches may enable rapid (same-day) diagnosis and treat-
ment in more than 80% of those patients with the worst
prognostic characteristics. Use of these approaches there-
fore has the potential to improve survival and these data
provide the basis to justify large-scale intervention trials.
We chose to study four different indices of disease
severity that reflected not only the degree of HIV-
associated immunodeficiency (CD4 cell counts) but also
other important aspects of the disease process. Patients
with a negative WHO symptom screen [9] represent those
with early ‘sub-clinical’ disease which tends to progress to
symptomatic disease over time, presumably as mycobacter-
ial load rises [23,24]. In contrast, those with chronic cough
of two or more weeks’ duration had more extensive
pulmonary radiographic disease. C-reactive protein is an
acute phase protein that reflects the systemic inflammatory
response to infection and has prognostic value in patients
with HIV-associated TB in this cohort [25]. Anemia is com-
mon in patients with HIV-associated TB, especially dissem-
inated disease, and is an independent predictor of mortality
in ART programs in sub-Saharan Africa [26-28].
The diagnostic sensitivity of Xpert MTB/RIF testing of
sputum was strongly associated with greater disease
severity across all prognostic indices. In the sickest patients
with the lowest CD4 cell counts, highest CRP concen-
trations or severe anemia, the sensitivity of a single
Xpert MTB/RIF test was more than twice that of smear
microscopy. Although high sensitivity of Xpert MTB/RIF
was found among those who subsequently died, failure of
linkage of patients with the results of tests done in centra-
lized National Health Laboratories Service laboratories
and delays in patients returning to the clinic following
recall clearly may have undermined any potential impact
on survival [29,30]. This illustrates the huge need for rapid
point-of-care diagnosis.
The observed higher sensitivity of Xpert MTB/RIF for
sputum-based TB diagnosis among those with the lowest
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Figure 2 The sensitivities (%) with 95% confidence intervals of urine-based (n = 81) and sputum-based (n = 86) diagnostic tests for
tuberculosis (TB). Data are shown stratified according to: (a) symptoms, (b) C-reactive protein (CRP) concentration (mg/L), (c) blood hemoglobin
concentration (g/dl), (d) blood CD4 cell count (cells/μL).
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CD4 cell counts appears to run contrary to the widely-held
dogma that sputum mycobacterial load declines linearly
with advancing immunodeficiency. However, the exist-
ing view-point is not well supported in the literature.
We have recently reported on over 13,000 unselected
cases of HIV-associated TB from Cape Town, South Africa
[31]. Although the proportion of pulmonary cases testing
sputum smear-positive initially declined in parallel with
lower CD4 cell counts in the range 500 to 200 cells/μL, the
overall relationship was non-linear with the proportion
testing smear-positive increasing as CD4 counts declined
further from 150 to zero cells/μL [31]. The patterns ob-
served in the present study are entirely consistent with
this and suggest that at progressively lower CD4 cell counts
below 150 cells/μL, the overall mycobacterial load rises sub-
stantially, facilitating microbiological diagnosis when using
appropriate clinical samples and diagnostic tools.
Sputum samples were obtained by a dedicated study
nurse with the assistance of nebulized hypertonic saline
as described in detail elsewhere [32]. The quality of sputum
samples is likely to be an important determinant of the
yield of TB diagnoses from sputum-based diagnostics and
is often much more difficult to obtain under routine pro-
gram conditions and especially among very sick in-patient
populations. A considerable advantage of urine-based TB
diagnosis is the ease and rapidity of obtaining and handling
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Figure 3 The sensitivities (%) with 95% confidence intervals of urine-based (n = 81) and sputum-based (n = 86) diagnostic tests for
tuberculosis (TB). Data are shown stratified according to vital status at 90 days.
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Figure 4 Venn diagrams showing total tuberculosis cases, deaths and the proportions diagnosed by different diagnostic assays. Data
are shown for 81 cases with complete data using: (a) sputum-based investigation with smear microscopy or Xpert MTB/RIF testing of two sputum
samples and (b) testing urine samples with either Determine TB-LAM or Xpert MTB/RIF.
Lawn et al. BMC Medicine 2013, 11:231 Page 7 of 10
http://www.biomedcentral.com/1741-7015/11/231
urine samples and fewer concerns about sample quality.
Urine-based diagnosis, therefore, offers a very important
alternative diagnostic approach [33].
Determine TB-LAM is a simple, low-cost lateral flow test
that is able to diagnose TB within 30 minutes and provides
a rapid means of screening for HIV-associated TB with
moderate sensitivity and high specificity among those with
the lowest CD4 cell counts [13,34]. This study extends our
previous observations to show that although the overall
sensitivity of Determine TB-LAM was low when screening
unselected HIV-infected patients, useful sensitivity was
observed among subsets of patients with poor prognostic
features. Thus, the assay might best be used to screen in
a targeted fashion HIV-infected patients with low CD4
counts and those with other poor prognostic characteristics
such as moderate or severe anemia.
The association of the Determine TB-LAM assay sen-
sitivity with blood hemoglobin concentration was par-
ticularly striking, detecting none of the TB cases who
had a blood hemoglobin of >11.0 g/dl but detecting all
cases with a hemoglobin of <8 g/dl. It is likely that
LAM antigenuria reflects disseminated mycobacteremia
[35] and possible bone marrow involvement with TB.
When retrospectively testing urine samples, Determine
TB-LAM correctly diagnosed TB from a single clinical
sample in all those who died during the three months
follow-up. This assay offers the fastest means of
screening for HIV-associated TB, permitting initiation
of treatment in the sickest patients pending the results
of further investigations.
The Xpert MTB/RIF assay may be used to test a wide
range of non-respiratory samples [11]. When testing
small volume (2.0 ml) urine samples, the diagnostic sen-
sitivity was not only greater among those with lower CD4
counts as previously reported [15], but was also higher
among those with higher CRP concentrations, severe
anemia and in those who later died. Xpert MTB/RIF de-
tects DNA from whole Mycobacterium tuberculosis bacilli
and so all patients with sputum culture-positive TB who
also tested urine Xpert MTB/RIF-positive, therefore, had
disseminated TB. Sensitivity is increased by concentrating
larger volumes of urine by centrifugation [36] and this adds
little to the laboratory processing time.
The finding of assay sensitivity varying substantially
according to symptom status and disease severity may ex-
plain some of the heterogeneity between the results of stud-
ies assessing the diagnostic accuracy of tests for TB. This
may well reflect differences between study populations. This
might explain why, for example, the reported sensitivity of
Xpert MTB/RIF for pulmonary TB was substantially lower
during community-based active case finding compared to
that observed during investigation of sick patients requiring
hospital admission (62.6% versus 86.1%, respectively)
[37,38]. Thus, studies of the accuracy of TB diagnostic
assays should characterize symptom profiles and disease
severity of participants.
Strengths of this study include the use of multiple in-
dices of disease severity; the use of sputum induction
to obtain high quality sputum samples; access to rigorous
quality-assured microbiology laboratories with use of liquid
culture as the diagnostic reference standard; the study
of both sputum-based and urine-based diagnostic ap-
proaches and the ascertainment of vital status at 90 days.
The cohort size and numbers of deaths, although limited,
were nevertheless sufficient to address the study hypoth-
esis. Weaknesses include the fact that this is a single study
site; TB status was ascertained at one time-point and in-
cluded only patients with sputum culture-positive disease;
urine-based assays were done retrospectively and did not
inform treatment decisions; and only small volumes of
urine were available for Xpert MTB/RIF testing, poten-
tially limiting the yield obtained by this means. We have
simply reported on factors affecting diagnostic sensitivity
as we have already reported on the specificities of these
assays in this cohort which all exceed 98% [13-15].
This study was observational and it cannot be deduced
whether use of these new diagnostic approaches would
be associated with improved survival.
Conclusion
In conclusion, sputum-based and urine-based TB diag-
nosis using Xpert MTB/RIF and Determine TB-LAM
assays permit rapid diagnosis of HIV-associated TB
among patients with advanced immunodeficiency and
especially among those with poor prognostic character-
istics. These data provide a strong rationale for large-
scale studies of the impact of the use of these assays on
survival and on the operational and economic feasibility
and sustainability of these approaches.
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